[GRG] Report: “The Case for Personalized Medicine,”

cut and paste the link below to get to the source:

http://ift.tt/1o508de
personalized-medicine/81250030/

Jun 25, 2014

Making the Case for Personalized Medicine

Making the Case for Personalized Medicine
Source: © Alexander Raths – Fotolia.com

Personalized medicine is gaining momentum, but it needs yet more
impetus to break into the healthcare mainstream, argues a new
report. Released on June 25 by the Personalized Medicine Coalition
(PMC), the report examines opportunities for the continued
development and adoption of personalized medicine as the cost of
genetic sequencing declines, the pharmaceutical industry increases
its commitment to personalized treatment, and the public policy
landscape evolves.

According to the report, personalized medicine is poised to:
◾ Shift the emphasis in medicine from reaction to prevention.
◾ Direct the selection of optimal therapy and reduce trial-and-
error prescribing.
◾ Help avoid adverse drug reactions.
◾ Increase patient adherence to treatment.
◾ Improve quality of life.
◾ Reveal additional or alternative uses for medicines and drug
candidates.
◾ Help control the overall cost of health care.

The report, which is entitled “The Case for Personalized Medicine,”
strikes a confident tone, citing progress along scientific,
technological, and commercial fronts. Advances include a more than
16,000-fold decrease in sequencing costs over the past 10 years, a
57% increase in products the last three years, and a steadily
growing number of drugs with labels that include pharmacogenomic
information. In 2006, there were 13 prominent examples of
personalized drugs, treatments, and diagnostics on the market. In
2011, there were 72, and today there are 113.

Despite these advances, the report soberly notes that technological
changes need to be accompanied by cultural and institutional
changes: “Such rapid developments … make it imperative for us to
encourage the development and adoption of personalized medicine. It
is essential to have appropriate coverage and payment policies, as
these will encourage continued investment in new molecular
diagnostics. We need regulatory guidelines that adapt to and
encourage the coupling of diagnostics and medicines that target
genetically defined populations. And professional education must be
modernized to prepare the next generation of doctors and other
health care professionals for personalized medicine.”

The report, now in its fourth edition, is scheduled to debut later
today at The Personalized Medicine and Diagnostics Forum at the
2014 BIO International Convention in San Diego. “BIO is very
pleased to co-host [the forum] with the PMC,” said Paul Sheives,
director of BIO’s diagnostics and personalized medicine policy.
“PMC’s The Case for Personalized Medicine defines the field and
contributes to our understanding of how developments in science and
technology are creating new opportunities to address unmet patient
needs.”

“In a time of unprecedented scientific breakthroughs and
technological advancements, personalized health care has the
capacity to detect the onset of disease at its earliest stages, pre-
empt the progression of disease, and, at the same time, increase
the efficiency of the health care system by improving quality,
accessibility, and affordability,” said Edward Abrahams, president
of the PMC. “We’ve come a long way, but we have a lot to do,
especially in education and advocacy.”

The PMC’s report offers these conclusions: “Personalized medicine
offers significant short- and long-term benefits, especially for
chronic and complex diseases. Payment and reimbursement policies
should not discourage interventions that may raise short-term costs
but improve clinical/cost value over time. Policies that recognize
the principles of personalized medicine will allow physicians to
individualize treatment plans for patients through the early
diagnosis of disease, target treatments to optimize clinical
outcomes, and prevent unnecessary hospitalizations and care, thus
reducing long-term costs.

“Innovators are responsible for developing the collective evidence
to justify the contention that personalized medicine can improve
outcomes while controlling costs. Except in the case of some
individual products, to date they have not proven that contention.
When they do, our argument will be more compelling.”

Advertisements

About Johnny Adams

My full-time commitment is to slow and ultimately reverse age related functional decline to increase healthy years of life. I’ve been active in this area since the 1970s, steadily building skills and accomplishments. I have a good basic understanding of the science of aging, and have many skills that complement those of scientists so they can focus on science to advance our shared mission. Broad experience Top skills: administration, management, information technology (data and programming), communications, writing, marketing, market research and analysis, public speaking, forging ethical win-win outcomes among stakeholders (i.e. high level "selling"). Knowledge in grant writing, fundraising, finance. Like most skilled professionals, I’m best described as a guy who defines an end point, then figures out how to get there. I enjoy the conception, design, execution and successful completion of a grand plan. Executive Director Gerontology Research Group (GRG). Manages Email discussion forum, web site, meetings and oversees supercentenarian (oldest humans, 110+ years) research. CEO / Executive Director Carl I. Bourhenne Medical Research Foundation (Aging Intervention Foundation), an IRS approved 501(c)(3) nonprofit. http://www.AgingIntervention.org Early contributor to Supercentenarian Research Foundation. Co-Founder Geroscience Healthspan Forum. Active contributor to numerous initiatives to increase healthy years of life. Co-authored book on conventional, practical methods available today to slow the processes of aging – nutrition, exercise, behavior modification and motivation, stress reduction, proper supplementation, damage caused by improper programs, risk reduction and others. Fundamental understanding of, and experience in the genomics of longevity (internship analyzing and curating longevity gene papers). Biological and technical includes information technology, software development and computer programming, bioinformatics and protein informatics, online education, training programs, regulatory, clinical trials software, medical devices (CAT scanners and related), hospital electrical equipment testing program. Interpersonal skills – good communication, honest, well liked, works well in teams or alone. Real world experience collaborating in interdisciplinary teams in fast paced organizations. Uses technology to advance our shared mission. Education: MBA 1985 University of Southern California -- Deans List, Albert Quon Community Service Award (for volunteering with the American Longevity Association and helping an elderly lady every other week), George S. May Scholarship, CA State Fellowship. BA psychology, psychobiology emphasis 1983 California State University Fullerton Physiological courses as well as core courses (developmental, abnormal etc). UCLA Psychobiology 1978, one brief but fast moving and fulfilling quarter. Main interest was the electrochemical basis of consciousness. Also seminars at the NeuroPsychiatric Institute. Other: Ongoing conferences, meetings and continuing education. Aging, computer software and information technology. Some molecular biology, biotech, bio and protein informatics, computer aided drug design, clinical medical devices, electronics, HIPAA, fundraising through the Assoc. of Fundraising Professionals. Previous careers include: Marketing Increasing skill set and successes in virtually all phases, with valuable experience in locating people and companies with the greatest need and interest in a product or service, and sitting across the table with decision makers and working out agreements favorable to all. Information Technology: Management, data analysis and programming in commercial and clinical trials systems, and bioinformatics and protein informatics. As IT Director at Newport Beach, CA based technology organization Success Family of Continuing Education Companies, provided online software solutions for insurance and financial professionals in small to Fortune 500 size companies. We were successful with lean team organization (the slower moving competition was unable to create similar software systems). Medical devices: At Omnimedical in Paramount CA developed and managed quality assurance dept. and training depts. for engineers, physicians and technicians. Designed hospital equipment testing program for hospital services division. In my early 20’s I was a musician, and studied psychology and music. Interned with the intention of becoming a music therapist. These experiences helped develop valuable skills used today to advance our shared mission of creating aging solutions.
This entry was posted in Uncategorized. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s